Condition: Myotonic Dystrophy 1 · Sponsor: Arrowhead Pharmaceuticals
This is a phase 1/2a double-blinded, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of ARO-DM1 compared to placebo in male and female subjects with type 1 myotonic dystrophy (DM1). Participants who have provided written informed consent and met all protocol eligibility requirements will be randomized to receive single (Part 1) or multiple (Part 2) doses of ARO-DM1 or placebo.
This description comes directly from the study's public registry record.
Medical Monitor · 626-304-3400 · ARO-DM1@arrowheadpharma.com
Always discuss trial participation with your own doctor first.
| Research Site | Liverpool, New South Wales, Australia | Recruiting |
| Research Site | Birtinya, Queensland, Australia | Recruiting |
| Research Site | Herston, Queensland, Australia | Recruiting |
| Research Site | Melbourne, Victoria, Australia | Recruiting |
| Research Site | Christchurch, New Zealand | Recruiting |
| Research Site | Taichung, Taiwan | Recruiting |
| Research Site | Taipei, Taiwan | Recruiting |
| Research Site | Taipei, Taiwan | Recruiting |
| Research Site | Bangkok, Bangkok, Thailand | Recruiting |
| Research Site | Hat Yai, Changwat Songkhla, Thailand | Recruiting |
| Research Site | Lampang, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06138743